本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Madrigal Pharmaceuticals, Inc.

511.58
-5.1600-1.00%
成交量:6.89萬
成交額:3,525.24萬
市值:117.95億
市盈率:-35.99
高:517.00
開:517.00
低:507.18
收:516.74
52周最高:615.00
52周最低:393.61
股本:2,305.55萬
流通股本:1,372.50萬
量比:0.29
換手率:0.50%
股息:- -
股息率:- -
每股收益(TTM):-14.2164
每股收益(LYR):-12.8501
淨資產收益率:-53.31%
總資產收益率:-17.84%
市淨率:22.52
市盈率(LYR):-39.81

資料載入中...

公司資料

公司名字:
Madrigal Pharmaceuticals, Inc.
交易所:
NASDAQ
成立時間:
2016
員工人數:
915
公司地址:
1001 Conshohocken State Road,Suite 2-350,West Conshohocken,Pennsylvania,United States
郵編:
19428
電話:
傳真:
- -
簡介:
Madrigal Pharmaceuticals, Inc.於2000年3月成立並在2001年7月開始運營。該公司是一家生物製藥公司,專註於為代謝功能障礙相關脂肪性肝炎提供新的治療方法。脂肪性肝炎是一種嚴重的肝病,其醫療需求高度未得到滿足,可導致肝硬化、肝衰竭、癌症、肝移植需求和過早死亡。該公司的藥物Rezifra是一種每日一次的口服肝臟導向甲狀腺激素受體β激動劑,旨在針對MASH的關鍵潛在原因。

董事

名稱
職位
Bill Sibold
President and Chief Executive Officer and Director
Julian C. Baker
Independent Chairman of the Board and Independent Director
Jacqualyn A. Fouse
Independent Director
James Daly
Independent Director
Kenneth M. Bate
Independent Director
Paul A. Friedman
Independent Director
Raymond Cheong
Independent Director
Richard S. Levy
Independent Director
Rebecca Taub
Director

股東

名稱
職位
Bill Sibold
President and Chief Executive Officer and Director
Mardi Dier
Executive Vice President and Chief Financial Officer
Rita Thakkar
Senior Vice President and Chief Accounting Officer
Carole Huntsman
Executive Vice President and Chief Commercial Officer
David Soergel
Executive Vice President and Chief Medical Officer
Shannon Kelley
Executive Vice President and Chief Legal Counsel